KB Financial Group Inc (KB) reports a 23.8% increase in net profit, driven by robust non-interest income, despite challenges from declining net interest margins.

Detailed price information for KB Financial Group Inc ADR (KB-N) from The Globe and Mail including charting and trades.

BAYRY wins FDA nod to expand Kerendia's label, making it the only approved non-steroidal MR antagonist for two major conditions.